Together, the above findings support the hypothesis that mutant KRas-dependent human cancer cells are vulnerable to GSK3α/β inhibition and that, in these cells, mutant KRas requires GSK3α/β to maintain tumor cell survival. Here, GSK3A is linked to neoplasm.